Abbott Laboratories vs Novo Nordisk

Abbott Laboratories (ABT), health care, and Novo Nordisk (NVO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Abbott Laboratories is worth $184.1B on the stock market and Novo Nordisk $179B: Abbott Laboratories is valued at 3% more. Abbott Laboratories trades at 39.7 times earnings and Novo Nordisk at 10.3; operating margins in their latest fiscal years were 18.2% and 41.3%. Over the past year Abbott Laboratories's share price has moved -17.3% and Novo Nordisk's -12.5%.

Key facts

Abbott Laboratories market value
$184.1B
Novo Nordisk market value
$179B
Abbott Laboratories P/E
39.7
Novo Nordisk P/E
10.3
Abbott Laboratories revenue
$44.3BFY to 2025-12-31
Novo Nordisk revenue
$45.9BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Abbott Laboratories vs Novo Nordisk: every measure side by side
Measure Abbott Laboratories Novo Nordisk
SectorHealth CareHealth Care
Country United States Denmark
Fiscal year ends2025-12-312025-12-31
Size
Market cap$184.1Bhigher$179Blower
Revenue$44.3Blower$45.9Bhigher
Earnings$6.5Blower$15.2Bhigher
Employees122,000higher68,794lower
Total assets$86.7Bhigher$80.6Blower
Valuation
P/E39.7higher10.3lower
P/S4.2higher3.9lower
P/B3.6—
Dividend yield2.35%—
Profitability
Operating margin18.2%lower41.3%higher
Balance sheet
Net assets$52.1Bhigher$28.8Blower
Total liabilities$33.9Blower$51.8Bhigher
Total debt$12.9Blower$19.4Bhigher
Cash on hand$8.5Bhigher$3.9Blower
Price change
Today-1.09%higher-2.38%lower
1 year-17.3%lower-12.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Abbott Laboratories / Novo Nordisk). Who owns ABT · Who owns NVO

Further comparisons

Learn

Questions and answers

Which is bigger, Abbott Laboratories or Novo Nordisk?

By market value, Abbott Laboratories is the larger: $184.1B against $179B for Novo Nordisk. By revenue in its latest fiscal year, Novo Nordisk is the larger: $45.9B against $44.3B for Abbott Laboratories.

Which has the higher P/E ratio?

Abbott Laboratories: 39.7, against 10.3 for Novo Nordisk. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Novo Nordisk: 41.3%, against 18.2% for Abbott Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Novo Nordisk: $19.4B, against $12.9B for Abbott Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Abbott Laboratories and Novo Nordisk?

In their latest 13F filings, John Overdeck and David Siegel (founders) holds both.

Cite this page

Funkfolio, “Abbott Laboratories vs Novo Nordisk”, data as of 17 November 2026. https://funkfolio.com/compare/abt-vs-nvo

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.